Monday, August 12, 2019

Biovie Looks To NASDAQ

Los Angeles-based BioVie, a biotech company developing treatments for liver cirrhosis, is looking to a public offering on the NASDAQ Capital Market, saying that it is offering up 1,311,189 shares of its stock on the NASDAQ Capital Market as BIVI. The company previously traded over-the-counter (OTC). The company's offering is being managed by ThinkEquit

The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please login in order to access this members-only content, or become a member.